Boao International Medical Center
Boao International Medical Center
China, Qionghai
Colon cancer treatment cost in China typically includes essential diagnostics like PET-CT scans and primary treatments such as colectomy, which runs from $16,500 to $24,500. For advanced cases, robotic surgery ranges from $24,500 to $49,500. Total expenses depend on the cancer stage and hospital tier. International patients usually find 50-70% savings compared to the United States. Key medical hubs include Guangzhou, Xiamen, and Beijing.
Typical Colon Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients seeking alternatives to traditional chemotherapy benefit from specialized minimally invasive centers. Fuda Cancer Hospital offers over 10 innovative therapies, including NanoKnife and cryosurgery, specifically for advanced cases. For those requiring precision radiation, Xiamen Humanity Hospital provides expert IMRT and VMAT protocols. JCI-accredited facilities in China combine advanced robotic technology with significant financial savings for international patients.
| China | Turkey | Austria | |
| Tomotherapy | from $17,500 | from $12,000 | from $30,000 |
| Radiation therapy for bowel cancer | from $10,500 | from $5,800 | from $6,944 |
| NanoKnife | from $22,500 | from $9,500 | from $25,000 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from $22,500 | from $6,500 | from $40,000 |
| Gastric polyps removal | from $1,800 | from $752 | from $5,000 |
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
Professor Liang Xiaoxiao is the Department Director and Chief Physician in Neurorehabilitation. She holds a master’s degree in neurology. She is skilled in neuromodulation for disorders of consciousness, cognition, and movement. Her focus includes cases from cerebrovascular disease, Parkinson’s disease, and related conditions. She also performs ultrasound-guided botulinum toxin injections for blepharospasm, hemifacial spasm, limb spasticity, sialorrhea, and neuralgia.
Accreditations and roles: Member of the Neurorehabilitation, Cognitive Disorder Rehabilitation, and Craniocerebral Trauma Rehabilitation Committees of the Chinese Association of Rehabilitation Medicine. Standing Member of the Cognitive Disorder Rehabilitation Committee of the Fujian Association of Rehabilitation Medicine. Vice Chair of the Dementia and Cognitive Disorder Committee of the Xiamen Preventive Medicine Association. Vice President of the Parkinson’s Disease and Movement Disorders Committee of the Xiamen Medical Doctor Association. Standing Member of the Neuromodulation Committee of the Xiamen Medical Doctor Association. Recipient of the Most Beautiful Physician of Xiamen City (2024).
Professor Zheng Qiu Hong is Director of the Cell Therapy Research Center and a National Senior Expert in Biotherapy. He is a Professor and Master’s Supervisor at Fujian Medical University. He has more than 30 years of clinical experience in tumor molecular biology and biotherapy. From 2012 to 2013, he was a visiting scholar in stem cell research at the University of Connecticut School of Life Sciences. He previously held leadership roles at Fujian Cancer Hospital. These roles included Director of the Tumor Molecular Biology Laboratory and Director of the Surgical Oncology Research Laboratory. He also served as Deputy Director of the Fujian Key Laboratory of Tumor Biotherapy and Deputy Director of the Biotherapy and Immunotherapy Center.
Appointments include Standing Committee Member of the Biotherapy Committee of the Chinese Research Hospital Association. He is also a Committee Member of the Tumor Immunology and Biotherapy Committee of the Chinese Society for Immunology. In addition, he is Deputy Chair of the Academic Committee of the Xiamen Cell Therapy Research Center at the First Affiliated Hospital of Xiamen University.
The 5-year relative survival rate for colon cancer in China is approximately 58% to 62%. Early-stage detection yields high survival rates between 85% and 96%. Outcomes correlate strongly with geographic location and the use of curative radical surgery over palliative care.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator in China. Fuda Cancer Hospital serves over 30,000 international patients. Xiamen Humanity Hospital manages around 1,000,000 patients annually. High-volume centers often provide faster access to specialized technologies like NanoKnife and CyberKnife M6 for complex cases.
Patient Consensus: Patients emphasize choosing tier-3 hospitals in major cities to ensure Western-level outcomes. Many recommend using specialized apps to track real-time follow-up statistics and manage post-operative care.
Colon cancer treatment in China focuses on surgical resection and minimally invasive techniques. Hospitals utilize laparoscopy for over 56% of cases to ensure faster recovery. Advanced centers combine specialized surgery with chemotherapy, targeted therapies, or immunotherapy based on genetic markers like KRAS and MSI status.
Bookimed Expert Insight: While most centers follow standard protocols, Fuda Cancer Hospital differentiates itself by applying over 10 types of minimally invasive therapies. Their focus on cryosurgery and vascular interventional therapy provides alternatives for patients who cannot tolerate aggressive chemotherapy after 30,000+ international cases.
Patient Consensus: Patients note that while surgery is the standard first-line approach, access to advanced diagnostics like PD-L1 testing often depends on whether you are in a major city center.
Stage 4 colon cancer is treatable in China through advanced multidisciplinary protocols in specialized oncology centers. Medical facilities utilize radical resection, NanoKnife ablation, and HIPEC to manage metastatic disease. Integration of modern drug therapies with traditional supportive care helps extend survival and maintain patient quality of life.
Bookimed Expert Insight: Patients seeking treatment in China should prioritize JCI-accredited facilities in major hubs like Guangzhou. Data shows clinics like Fuda Cancer Hospital focus on minimally invasive therapies like cryosurgery and NanoKnife. These options serve as alternatives for those who may not tolerate standard high-dose chemotherapy well.
Patient Consensus: Patients note that getting imaging reviewed at a major Tier-1 city hospital is essential for accurate staging. Many emphasize that while costs for multimodal therapy are significant, the expertise in top academic centers is comparable to Western standards.
Traditional Chinese Medicine (TCM) serves as a supportive integrative therapy for colon cancer in China. It combines herbal formulas, acupuncture, and lifestyle practices with surgery or chemotherapy to improve quality of life. These protocols focus on reducing treatment side effects and strengthening the immune response.
Bookimed Expert Insight: Integrative care in China often combines ancient practices with advanced technology at the same facility. For example, Jinshazhou Hospital of Guangzhou University of Chinese Medicine offers CyberKnife M6 radiosurgery alongside traditional protocols. Our data shows these specialized centers provide comprehensive packages around $7,900 that include medical consultations and hospital stays.
Patient Consensus: Patients note that IV herbal drips and acupuncture are often provided directly in the hospital ward. They emphasize using these therapies to manage pain and speed up wound healing after a colon resection.
China provides specialized treatments for inoperable tumors including cryosurgery, NanoKnife, and advanced immunotherapy. Facilities like Fuda Cancer Hospital are Joint Commission International (JCI) accredited. They specialize in treating late-stage cancer using over 10 types of minimally invasive therapies to manage complex cases.
Bookimed Expert Insight: While many countries focus on single-modality treatments for late-stage cases, specialized Chinese centers often combine cryosurgery with vascular intervention. Fuda Cancer Hospital has utilized this combined approach for over 30,000 patients from 100 countries. This high volume of international cases suggests a robust infrastructure for managing complex, multi-stage treatment protocols that may not be available elsewhere.
Patient Consensus: Patients with advanced tumors note that while treatments like CyberKnife can shrink inoperable lesions, the physical toll and fatigue are significant. Many emphasize the importance of verifying trial data before starting newer immunotherapies due to varying clinical outcomes.